Why Revolution Medicines Inc (RVMD) Stock Is Rising
As of 2026-11-12, Revolution Medicines Inc (RVMD) has a next-year EPS growth estimate of 65.34%. Featured in our EPS revision report on 2026-09-28.
Why RVMD Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Revolution Medicines Inc's next-year EPS growth estimate from 38.96% to 56.68% on 2026-11-05.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +8.66 pp to 65.34% across 2 upward revisions.
- !Largest Single-Day Revision: +6.02 pp on 2026-11-06 (56.68% → 62.70%).
- ·Current-Year Growth: Projected at -43.04%, supporting the forward estimate revision.
News Context
The primary structural driver is the 2026-11-05 analyst upgrade to next-year EPS growth, from 38.96% to 56.68% (+17.72 pp). The RASONQUE launch headlines, including revenue forecasts being crushed and a “historic” launch, plausibly connect to that revision by supporting stronger earnings expectations. Momentum has continued beyond the initial upgrade: the current estimate is 65.34%, with a net +8.66 pp change
Generated 2026-11-12 · news as of 2026-11-12
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 65.34%
- EPS growth this year
- -43.04%
- EPS next quarter (est)
- -$1.21
- Last price
- $176.35
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 65.34% | -43.04% | -$1.21 | $176.35 |
| 2026-11-11 | 65.34% | -43.04% | -$1.21 | $180.70 |
| 2026-11-10 | 65.34% | -43.04% | -$1.21 | $193.06 |
| 2026-11-09 | 65.41% | -43.13% | -$1.20 | $200.15 |
| 2026-11-07 | 62.70% | -43.26% | -$1.19 | $192.28 |
| 2026-11-06 | 62.70% | -43.26% | -$1.19 | $192.28 |
| 2026-11-05 | 56.68% | -45.56% | -$1.31 | $177.65 |
| 2026-11-04 | 38.96% | -59.45% | -$2.35 | $199.70 |
| 2026-11-03 | 38.96% | -59.45% | -$2.35 | $194.23 |
| 2026-11-02 | 38.96% | -59.45% | -$2.35 | $188.17 |
| 2026-10-31 | 38.96% | -59.45% | -$2.35 | $191.31 |
| 2026-10-30 | 38.96% | -59.45% | -$2.35 | $191.31 |
| 2026-10-29 | 38.96% | -59.45% | -$2.35 | $190.27 |
| 2026-10-28 | 38.96% | -59.45% | -$2.35 | $188.72 |
| 2026-10-27 | 38.96% | -59.45% | -$2.35 | $186.22 |
| 2026-10-26 | 38.96% | -59.45% | -$2.35 | $183.90 |
| 2026-10-23 | 38.96% | -59.45% | -$2.35 | $186.99 |
| 2026-10-22 | 38.96% | -59.45% | -$2.35 | $187.69 |
| 2026-10-21 | 38.55% | -59.59% | -$2.36 | $194.28 |
| 2026-10-20 | 38.15% | -59.42% | -$2.34 | $196.55 |
| 2026-10-19 | 38.15% | -59.42% | -$2.34 | $182.15 |
| 2026-10-16 | 37.96% | -59.42% | -$2.34 | $177.96 |
| 2026-10-15 | 39.75% | -59.46% | -$2.35 | $189.26 |
| 2026-10-14 | 39.76% | -59.49% | -$2.35 | $193.52 |
| 2026-10-13 | 39.72% | -59.49% | -$2.35 | $188.44 |
| 2026-10-12 | 39.72% | -59.49% | -$2.35 | $193.95 |
| 2026-10-11 | 39.12% | -59.75% | -$2.35 | $189.76 |
| 2026-10-10 | 39.12% | -59.75% | -$2.35 | $189.76 |
| 2026-10-09 | 39.12% | -59.75% | -$2.35 | $189.76 |
| 2026-10-08 | 39.17% | -59.60% | -$2.35 | $188.12 |
Reports Featuring RVMD
Recent News
- Revolutions Rasonque off to best cancer drug launch in historyBioPharma Dive
- Revolutions Rasonque off to best cancer drug launch in historyBioPharma Dive
- This pancreatic cancer treatment is on track for 'one of the best drug launches of all time'MarketWatch
- Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?Investor's Business Daily
- Revolution Medicines' RASONQUE Launch Crushes Revenue Forecasts, But The First Quarter Is Hard To ExtrapolateEarnings Whispers
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressGlobeNewswire
- Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026GlobeNewswire
- Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung CancerGlobeNewswire
- Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness studyBioPharma Dive
- Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness studyBioPharma Dive
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Revolution Medicines Inc (RVMD) stock go up recently?▾
Revolution Medicines Inc (RVMD) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 38.96% to 56.68% on 2026-11-05. Since detection, the estimate has moved up a net +8.66 pp to 65.34%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Revolution Medicines Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Revolution Medicines Inc (RVMD) has a next-year EPS growth estimate of 65.34%, based on analyst consensus.
When was the latest EPS estimate revision for RVMD?▾
The most recent revision occurred on 2026-11-10, when analysts adjusted the next-year EPS growth estimate from 65.41% to 65.34%.
What sector and industry does Revolution Medicines Inc belong to?▾
Revolution Medicines Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RVMD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Revolution Medicines Inc (RVMD) appears here because it was detected by our daily top-EPS-revision-performer screen.